Replicel releases safety, efficacy data on RCH-01 DSCC regenerative cell therapy for baldness, thinning hair.
According to data released by Replicel on March 14, 2017, "The five-year trial data set has confirmed the complete safety profile of a high-dose of dermal sheath cup cells (DSCC) for patients with pattern baldness due to androgenetic alopecia."
DSCC therapy is the keystone technology for Replicel's RCH-01 product. Replicel reports that the first-in-human data on long-term safety endpoints for RCH-01 successfully met it's endpoints as they move forward toward further research, development and commercialization of the hair loss product in collaboration with Japanese company Shiseido.
According to Replicel, histological examination of the injection sites via biopsies at 6, 12, 24 and 60 months after treatment on 19 patients revealed no significant pathology (tumor, granuloma, foreign body formation, etc.)
In addition, efficacy data--while not statistically significant--revealed that there was a overall stabilization of hair loss in all participants as well as up to a 21% improvement in hair density in a top tier responder (average 4.2% increase in hair density overall).
Replicel Chief Scientific Officer, Dr. Kevin McElwee, alluded to further research focusing on designing optimal cell number (dosage) and injection frequency (timing) to optimize peak efficacy in terms of increased hair density. From his statements, it appears that smaller cell doses and more frequent treatment sessions may be used to achieve a superior effect in terms of increasing hair regrowth.
“In summary,” stated RepliCel’s President and CEO, R. Lee Buckler, “we are very pleased with the results of this first-in-human study and are excited to move this product forward into the next phases of development.”
At Bauman Medical in Boca Raton, FL we are actively watching this--and other--continuing research in the field of cell therapy for hair regrowth in androgenetic alopecia (pattern baldness in men and women). We are hoping to see the hair measurements of the hair regrowth performed with the HairCheck device which can be used to measure results from hair loss treatments such as PRP with Extracellular Matrix, SVF, MSCs, adipose stem cells or other cell therapy, compounded Formula 82M minoxidil, topical finasteride, laser therapy, hair transplantation and more.